Trials / Withdrawn
WithdrawnNCT02965417
Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
An Open-label, Multicenter, Phase 2 Trial Investigating Sym004 in Patients With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies and Documented Mutation of Extra Cellular Domain of EGFR (ECD-EGFR)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Symphogen A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm, phase 2, open-label, multicenter trial in patients with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and documented mutation of extra cellular domain EGFR (ECD-EGFR).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sym004 | Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR). |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2017-01-01
- Completion
- 2017-01-01
- First posted
- 2016-11-16
- Last updated
- 2017-02-01
Source: ClinicalTrials.gov record NCT02965417. Inclusion in this directory is not an endorsement.